Canagliflozin, 100 mg

DRUG6 trials

Conditions

AlbuminuriaDiabetes Mellitus, Type 2HealthyHealthy Volunteers

Phase 1

A Pharmacokinetic Dose Proportionality Study of Canagliflozin in Healthy Volunteers

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Healthy

Start: 2011-05-31End: 2011-08-31Updated: 2012-08-17

Treatment Differences Between Canagliflozin and Placebo in Insulin Secretion in Subjects With Type 2 Diabetes Mellitus (T2DM)

CompletedNCT02009488

Janssen Research & Development, LLCDiabetes Mellitus, Type 2

Start: 2014-09-08End: 2017-01-03Updated: 2018-01-04

A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components

CompletedNCT02065752

Janssen Research & Development, LLCHealthy Volunteers

Start: 2014-02-28End: 2014-04-30Updated: 2014-06-17

A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components in Healthy Fed Participants

CompletedNCT02077803

Janssen Research & Development, LLCHealthy

Start: 2014-03-31End: 2014-07-31Updated: 2014-09-03

Phase 4

A Study of the Effects of Canagliflozin (JNJ-28431754) on Renal Endpoints in Adult Participants With Type 2 Diabetes Mellitus

CompletedNCT01989754

Janssen Research & Development, LLCAlbuminuria, Diabetes Mellitus, Type 2

Start: 2014-01-16End: 2017-02-23Updated: 2018-12-11

A Study to Evaluate the Efficacy and Safety of the Addition of Canagliflozin in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin and Sitagliptin

CompletedNCT02025907

Janssen Research & Development, LLCDiabetes Mellitus, Type 2

Start: 2014-02-28End: 2015-09-30Updated: 2016-10-31

Cardiovascular Diabetology2025-05-151 citations

Canagliflozin may increase thromboembolic events in males with erythrocytosis but not in females

Blood Advances2025-04-167 citations

The Efficacy and Safety of Canagliflozin by Frailty Status in Participants of the <scp>CANVAS</scp> and <scp>CREDENCE</scp> Trials

Journal of the American Geriatrics Society2025-03-195 citations

Effects of Canagliflozin on Total Heart Failure Events Across the Kidney Function Spectrum: Participant-Level Pooled Analysis from the CANVAS Program and CREDENCE Trial

European Journal of Heart Failure2024-06-264 citations

Primary and Secondary Cardiovascular and Kidney Prevention With Canagliflozin: Insights From the CANVAS Program and CREDENCE Trial

Journal of the American Heart Association2024-01-194 citations

Canagliflozin, Blood Pressure Variability, and Risk of Cardiovascular, Kidney, and Mortality Outcomes: Pooled Individual Participant Data From the CANVAS and CREDENCE Trials

Journal of the American Heart Association2023-06-226 citations

Canagliflozin and Metabolic Associated Fatty Liver Disease in Patients With Diabetes Mellitus: New Insights From CANVAS

The Journal of Clinical Endocrinology & Metabolism2023-05-0733 citations

Extremes of both weight gain and weight loss are associated with increased incidence of heart failure and cardiovascular death: evidence from the CANVAS Program and CREDENCE.

2023-04-297 citations

Cardiovascular Effects of Canagliflozin in Relation to Renal Function and Albuminuria.

2022-11-017 citations

Kidney outcomes using a sustained ≥40% decline in eGFR: A meta-analysis of SGLT2 inhibitor trials.

2021-06-1525 citations

Effects of canagliflozin on myocardial infarction: a <i>post hoc</i> analysis of the CANVAS programme and CREDENCE trial

Cardiovascular Research2021-04-0619 citations

Relative and Absolute Risk Reductions in Cardiovascular and Kidney Outcomes With Canagliflozin Across KDIGO Risk Categories: Findings From the CANVAS Program.

2020-09-2151 citations

Different eGFR Decline Thresholds and Renal Effects of Canagliflozin: Data from the CANVAS Program

Journal of the American Society of Nephrology2020-07-2121 citations

Mediators of the Effects of Canagliflozin on Heart Failure in Patients With Type 2 Diabetes.

2019-10-29112 citations

Canagliflozin and fracture risk in individuals with type 2 diabetes: results from the CANVAS Program.

2019-08-1046 citations

Canagliflozin and Stroke in Type 2 Diabetes Mellitus

Stroke2018-12-2873 citations

Cardiovascular and Renal Outcomes With Canagliflozin According to Baseline Kidney Function

Circulation2018-06-25245 citations

Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials.

2018-06-21446 citations

Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus

Circulation2018-03-11469 citations

Impact of Canagliflozin Treatment on Health-Related Quality of Life among People with Type 2 Diabetes Mellitus: A Pooled Analysis of Patient-Reported Outcomes from Randomized Controlled Trials

Patient2018-01-0810 citations

7 more papers not shown

Canagliflozin, 100 mg

Sponsors

Conditions

Phase 1

Phase 4

Related Papers